HIPEC and conventional intraperitoneal chemotherapy both deliver chemotherapy directly inside the abdomen, but they are not the same treatment. HIPEC uses heated chemotherapy for a limited period around the time of cytoreductive surgery. Conventional intraperitoneal chemotherapy—often called IP chemotherapy—uses chemotherapy placed into the abdomen without the same heated, single-operation approach and may be delivered over repeated treatment cycles.
Neither method is automatically better for every woman with ovarian cancer. The choice depends on when surgery is performed, how much visible cancer can be removed, previous chemotherapy, general health, kidney function, the medicines and protocol available, and the experience of the treating centre.
On This Page
HIPEC or IP Chemotherapy: What Is the Short Answer?
For a selected woman with advanced ovarian cancer undergoing cytoreductive surgery, HIPEC may be considered as part of the operation. The strongest evidence for HIPEC comes from the OVHIPEC-1 trial (2018), in women with stage 3 cancer who had three cycles of chemotherapy before surgery (interval surgery); its value at upfront (surgery-first) operations is not proven. It is not right for everyone and is not a guaranteed cure; see HIPEC eligibility and treatment. Conventional IP chemotherapy is a different regional-chemotherapy strategy that can expose cancer cells in the abdomen to high drug concentrations over a different schedule.
A 2025 real-world study directly comparing these approaches did not find a statistically certain difference in progression-free or overall survival across the full study population. That result does not prove the treatments are identical. It means the study could not show that one was superior overall, and the best choice remains individual.
What Is the Difference Between HIPEC and Intraperitoneal Chemotherapy?
| Feature | HIPEC | Conventional IP chemotherapy |
|---|---|---|
| Full name | Hyperthermic intraperitoneal chemotherapy | Intraperitoneal chemotherapy |
| Temperature | Chemotherapy solution is heated, commonly to approximately 41–43°C under a controlled protocol. | Chemotherapy is not delivered using the same heated perfusion process. |
| Timing | Usually delivered in the operating theatre during or immediately after cytoreductive surgery. | May be delivered after surgery through an abdominal access device over planned treatment cycles. |
| Number of treatments | Usually one intraoperative treatment within the surgical plan. | Often involves repeated administrations according to the chosen regimen. |
| Relationship to surgery | Closely linked to cytoreductive surgery and the ability to remove visible disease. | Requires appropriate surgical and medical planning but is not the same single operative perfusion. |
| Patient language | Heated chemo, hot chemotherapy, abdomen-wash chemotherapy or garam chemo. | Chemo through the abdomen, abdominal chemotherapy, IP chemo, or in Hindi pet ke andar chemo (पेट के अंदर कीमोथेरेपी). |
Both are forms of regional chemotherapy. They aim to expose cancer cells on the abdominal lining to a higher local drug concentration than intravenous treatment alone. Drug penetration is limited, so neither method can compensate for visible tumour that should have been removed safely.
How Is Each Treatment Given?
HIPEC during cytoreductive surgery
The surgeon first performs cytoreductive surgery (CRS), also called debulking surgery, to remove visible cancer. If the operative findings and the agreed protocol support HIPEC, tubes are positioned in the abdominal cavity and heated chemotherapy solution is circulated for a defined period. The solution is then drained and the operation is completed.
The treatment is given while the patient is under anaesthesia. HIPEC adds time and physiological stress to an already major operation, so kidney function, fluid balance, temperature, blood counts and other measures require close monitoring.
Conventional intraperitoneal chemotherapy
Conventional IP chemotherapy uses a catheter or access device to deliver chemotherapy into the abdominal cavity. Depending on the regimen, treatment may be repeated on scheduled days or cycles and may be combined with intravenous chemotherapy.
Because it is administered across treatment cycles, catheter blockage, infection, abdominal discomfort and the ability to complete the planned course can influence its usefulness. Exact protocols differ; “IP chemotherapy” is not one universal drug schedule.
What Did the 606-Patient HIPEC-versus-IP Study Find?
The study published in The Oncologist reviewed 606 women with Stage II–IV ovarian cancer treated between 2013 and 2024 after cytoreductive surgery. Of these, 335 received HIPEC and 271 received conventional IP chemotherapy. The researchers used statistical adjustment to make the groups more comparable, but it remained a retrospective study rather than a randomised trial.
After a median follow-up of about 26 months:
- disease progression was recorded in 40.6% of the HIPEC group and 55.0% of the IP group;
- the adjusted difference in progression-free survival did not reach statistical significance;
- mortality was 13.2% in the HIPEC group and 22.5% in the IP group; and
- the adjusted overall-survival difference was also not statistically significant.
These figures should not be interpreted as proof that HIPEC reduced progression or deaths by the simple difference between percentages. Treatment was not randomly assigned, follow-up was relatively short for survival comparisons, and unmeasured differences between the groups may remain despite statistical adjustment.
The practical conclusion is that HIPEC did not demonstrate clear overall superiority to conventional IP chemotherapy in this study. It supports careful selection rather than a rule that every suitable ovarian-cancer patient should receive heated treatment.
Does BRCA Status Decide Whether HIPEC or IP Chemotherapy Is Better?
No. BRCA status alone should not be used to choose HIPEC. The study’s exploratory analyses suggested that some BRCA-defined groups might experience different progression patterns. These subgroup findings were not the primary proof of the study and need confirmation in prospective research.
BRCA1 and BRCA2 results remain important in ovarian cancer because they can affect hereditary-risk counselling and eligibility for treatments such as PARP inhibitors. That is a separate decision from whether heated or conventional intraperitoneal chemotherapy is appropriate.
If a report says BRCA-positive, BRCA-negative, wild-type, HRD-positive or HRD-negative, ask the team to explain how that result changes each part of the treatment plan. A subgroup trend should not be presented as a guarantee of HIPEC benefit.
Who Might Be Considered for Treatment Inside the Abdomen?
Possible suitability depends on the cancer type, stage and timing of surgery. Factors commonly reviewed include:
- epithelial ovarian, fallopian-tube or primary peritoneal cancer;
- the distribution of disease inside and outside the abdomen;
- whether complete or near-complete cytoreductive surgery is achievable;
- whether surgery is primary, interval after neoadjuvant chemotherapy, or for recurrence;
- response to platinum-based chemotherapy;
- kidney, liver, bone-marrow and nutritional function;
- fitness for a long operation or repeated abdominal treatment;
- previous abdominal surgery, infection or adhesions;
- the treatment protocol and experienced team available; and
- the patient’s priorities after discussing expected benefit and burden.
Stage 3 or Stage 3C disease does not automatically establish eligibility. Similarly, recurrent ovarian cancer is not automatically an indication for HIPEC. The evidence differs by treatment setting.
How Do Side Effects and Recovery Differ?
Many risks arise from cytoreductive surgery itself: bleeding, infection, blood clots, chest problems, bowel complications, kidney injury, slow return of bowel function and delayed recovery. HIPEC can add operating time and may contribute to fluid, temperature, kidney or blood-count changes depending on the medicine used.
After cytoreductive surgery with HIPEC, most women stay in hospital about 10–14 days, including 3–5 days in intensive care. For a step-by-step guide, read about preparation and recovery around HIPEC.
In the 606-patient comparison, low albumin was common in both groups. Abdominal distension and wound separation were reported more often in the HIPEC group, while nausea and rash occurred more often with conventional IP treatment. These are group findings and do not predict an individual patient’s experience.
Conventional IP chemotherapy can also create catheter-related problems, infection, pain and difficulty completing every planned treatment. Recovery therefore should be compared as a complete pathway: the operation, the regional treatment, intravenous chemotherapy, hospital visits and the possibility of interruptions.
After either approach, contact the treating team promptly for fever, worsening abdominal pain or swelling, persistent vomiting, inability to drink, wound discharge or opening, breathlessness, leg swelling or very low urine output.
How Do Doctors Decide Between HIPEC, IP Chemotherapy and Other Options?
The first decision is not “heated or unheated?” It is the complete ovarian-cancer treatment strategy. The multidisciplinary team considers whether surgery is appropriate now, whether chemotherapy should come first, whether all visible cancer can be removed and which systemic and maintenance treatments are indicated.
The comparison may include:
- cytoreductive surgery with HIPEC;
- cytoreductive surgery without HIPEC followed by intravenous chemotherapy;
- conventional IP plus intravenous chemotherapy in an appropriate protocol;
- additional systemic chemotherapy before reconsidering surgery;
- secondary cytoreductive surgery for a carefully selected recurrence; or
- non-surgical systemic or supportive treatment when major surgery is unlikely to help.
Local availability should not be disguised as medical superiority. Ask which alternatives the centre can provide and whether the recommendation would change if every option were available.
Questions to Ask Your Cancer Team
- Are you recommending HIPEC, conventional IP chemotherapy or both intravenous and IP treatment?
- Is my operation primary, interval or for recurrence?
- Which evidence applies to that exact setting?
- Do you expect complete cytoreduction?
- Which drug, temperature, duration and number of treatments are planned?
- What benefit might this add over surgery and intravenous chemotherapy alone?
- What additional complications and hospital visits should I expect?
- Does my BRCA or HRD result change this choice, or only later maintenance treatment?
- What would make you cancel HIPEC during the operation?
- How soon should the next chemotherapy begin?
- What experience does the hospital have with this exact protocol?
Frequently Asked Questions
Is HIPEC the same as intraperitoneal chemotherapy?
HIPEC is one form of intraperitoneal chemotherapy, but the terms are not interchangeable. HIPEC uses heated perfusion around surgery. Conventional IP chemotherapy uses a different temperature, timing and often repeated cycles.
Is HIPEC better than IP chemotherapy?
Not for everyone. The recent real-world comparison did not show a statistically certain progression or survival advantage for HIPEC across the whole population. Randomised-trial evidence (OVHIPEC-1, 2018) supports HIPEC at interval surgery after three cycles of chemotherapy, while benefit at upfront surgery is not proven, so context matters.
Does heated chemotherapy replace ovarian-cancer surgery?
No. HIPEC targets microscopic disease and cannot replace cytoreductive surgery when visible cancer can and should be removed safely.
Does heated chemotherapy replace intravenous chemotherapy?
Usually no. HIPEC is one component of a broader plan. Most women considered for it also receive systemic chemotherapy before or after surgery.
Will BRCA testing tell me whether I need HIPEC?
No. BRCA testing is important for inherited risk and treatment planning, but the exploratory subgroup findings from one retrospective comparison are not enough to use BRCA alone as a HIPEC-selection test.
Is IP chemotherapy given through a drip in the arm?
IP chemotherapy is placed into the abdominal cavity through an access system. Some treatment schedules combine it with intravenous chemotherapy through a vein.
Which treatment has the easier recovery?
There is no universal answer. HIPEC adds treatment to a major operation, while conventional IP therapy may require repeated administrations and catheter care. Compare the entire pathway and your individual risks.
Related Guidance and Medical Sources
Read the general guide to HIPEC treatment and recovery, learn how to choose a CRS-HIPEC specialist, understand cytoreductive surgery, or review the complete ovarian-cancer treatment pathway.